AATS 102nd Annual Meeting

Boston, MA  |  Booth #1623

May 14 – 17, 2022

Join us during the AATS Welcome Reception

Saturday, May 14th at 6:00 pm 

Champagne Toast – New Brand Celebration | Cupcakes | Lattes | Discussions

Click the tabs below to learn more about the additional activities happening at AATS this year. We look forward to connecting with Boston, MA.

You are Cordially Invited to Attend a Special Dinner Symposium*

Advancing Aortic Technologies with Purpose

Sunday, May 15th | 6:30 – 8:30 PM

Sheraton Boston Hotel | Grand Ballroom

 

Agenda Overview

6:30 PM – 7:00 PM Cocktails & Live Music

7:00 PM – 8:30 PM Dinner & Discussion

 

RSVP Today, Space is Limited

 

RSVP Today

AMDS for Acute TAAD: Global Experience & PERSEVERE US Pivotal Study

 

Michael Moon, MD

Mazankowski Alberta Heart Institute, Canada

The Ross Procedure: Time to Revisit the Guidelines?

 

Ismail El-Hamamsy, MD PhD

Mount Sinai Hospital, USA

RSVP Today, Space is Limited

 

RSVP Today

 

*This industry symposium will be held in conjunction with the AATS Annual Meeting. It is not part of the official AATS scientific program. Continuing Medical Education (CME) credit for this activity is not offered by AATS.

Key Program Highlights

This year AATS has put together a top-notch scientific program, be sure to check out some key sessions we found interesting. Please keep in mind that you must be registered with the annual meeting to attend any of the scientific sessions.

Click Here to view the AATS 102nd Annual Meeting Full Scientific Sessions

Ross Procedure: Expanding Indications and Outcomes

Presentation Date: Saturday, May 14, 2022

Presentation Time: 5:00PM EST

Speaker: Ismail El-Hamamsy, Mount Sinai Hospital, USA

 

3-Year Outcomes of the Dissected Aorta Repair Through Stent Implantation Trial

Presentation Date: Monday, May 16, 2022

Presentation Time: 08:30-08:45 EDT

Speaker: Michael Moon, MD, Mazankowski Alberta Heart Institute, Canada

Note: All products and indications are not available/approved in all markets.

PERSEVERE*

A Prospective, Single Arm, Multi-Center Clinical Investigation to Evaluate the Safety and Effectiveness of AMDS* in the Treatment of Acute Debakey Type I Dissection Pivotal IDE Study

PROACT Xa**

Prospective Randomized Oral Anticoagulation Clinical Trial for Patients with an On-X Aortic Mechanical Valve – Factor Xa Inhibitor

*Note: US Investigational Device Only – not approved for commercial use in the US. 

**Disclaimer: The On-X Aortic Valve is not currently approved by the FDA for use with apixaban or any other anticoagulation, except vitamin K antagonist. ELIQUIS® is a registered trademark of the Bristol-Myers Squibb Company. Neither Artivion nor the PROACT Xa Trial are affiliated with, sponsored, or endorsed by the Bristol-Myers Squibb Company.